$PRTA
PROTHENA CORP PUBLIC LTD CO Stock $prta

$prta Overview Financials Valuation SEC Filings Company Website

2022 Q1 Form 10-Q Financial Statement

#000155905322000023 Filed on May 05, 2022

Income Statement

Concept	2022 Q1	2021 Q1
Revenue	$1.153M	$160.0K
YoY Change	620.63%	13.48%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$11.84M	$11.13M
YoY Change	6.33%	14.27%
% of Gross Profit
Research & Development	$27.26M	$21.14M
YoY Change	28.93%	38.67%
% of Gross Profit
Depreciation & Amortization	$182.0K	$304.0K
YoY Change	-40.13%	-20.83%
% of Gross Profit
Operating Expenses	$39.10M	$32.27M
YoY Change	21.16%	29.13%
Operating Profit	-$37.94M	-$32.11M
YoY Change	18.17%	29.22%
Interest Expense	$53.00K	$10.00K
YoY Change	430.0%	-99.12%
% of Operating Profit
Other Income/Expense, Net	-$17.00K	$34.00K
YoY Change	-150.0%	-96.95%
Pretax Income	-$37.96M	-$32.08M
YoY Change	18.35%	35.14%
Income Tax	-$1.700M	$4.700M
% Of Pretax Income
Net Earnings	-$36.29M	-$36.74M
YoY Change	-1.21%	55.86%
Net Earnings / Revenue	-3147.44%	-22959.38%
Basic Earnings Per Share	-$0.78	-$0.91
Diluted Earnings Per Share	-$0.78	-$0.91
COMMON SHARES
Basic Shares Outstanding	46.70M shares	40.25M shares
Diluted Shares Outstanding	46.70M shares	40.25M shares

Balance Sheet

Concept	2022 Q1	2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$543.0M	$343.0M
YoY Change	58.31%	-2.75%
Cash & Equivalents	$543.0M	$343.0M
Short-Term Investments
Other Short-Term Assets	$12.63M	$9.400M
YoY Change	34.32%	38.24%
Inventory
Prepaid Expenses
Receivables		$1.000K
Other Receivables		$0.00
Total Short-Term Assets	$555.6M	$352.3M
YoY Change	57.71%	-2.05%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.865M	$2.295M
YoY Change	-18.74%	-35.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$2.319M	$338.0K
YoY Change	586.09%	-69.69%
Total Long-Term Assets	$25.79M	$27.42M
YoY Change	-5.93%	-30.99%
TOTAL ASSETS
Total Short-Term Assets	$555.6M	$352.3M
Total Long-Term Assets	$25.79M	$27.42M
Total Assets	$581.4M	$379.7M
YoY Change	53.12%	-4.93%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$9.316M	$4.212M
YoY Change	121.18%	27.75%
Accrued Expenses	$16.72M	$18.50M
YoY Change	-9.61%	43.41%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$36.50M	$23.46M
YoY Change	55.59%	37.28%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$553.0K	$553.0K
YoY Change	0.0%	0.0%
Total Long-Term Liabilities	$106.0M	$121.7M
YoY Change	-12.86%	-4.41%
TOTAL LIABILITIES
Total Short-Term Liabilities	$36.50M	$23.46M
Total Long-Term Liabilities	$106.0M	$121.7M
Total Liabilities	$142.5M	$145.1M
YoY Change	-1.8%	0.52%
SHAREHOLDERS EQUITY
Retained Earnings	-$752.3M	-$819.8M
YoY Change	-8.23%	17.88%
Common Stock	$467.0K	$442.0K
YoY Change	5.66%	10.78%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$438.9M	$234.6M
YoY Change
Total Liabilities & Shareholders Equity	$581.4M	$379.7M
YoY Change	53.12%	-4.93%

Cashflow Statement

Concept	2022 Q1	2021 Q1
OPERATING ACTIVITIES
Net Income	-$36.29M	-$36.74M
YoY Change	-1.21%	55.86%
Depreciation, Depletion And Amortization	$182.0K	$304.0K
YoY Change	-40.13%	-20.83%
Cash From Operating Activities	-$37.42M	-$33.67M
YoY Change	11.14%	45.32%
INVESTING ACTIVITIES
Capital Expenditures	-$22.00K	-$50.00K
YoY Change	-56.0%	150.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$22.00K	-$48.00K
YoY Change	-54.17%	118.18%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$78.37M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$1.337M	$81.33M
YoY Change	-98.36%	53758.94%
NET CHANGE
Cash From Operating Activities	-$37.42M	-$33.67M
Cash From Investing Activities	-$22.00K	-$48.00K
Cash From Financing Activities	$1.337M	$81.33M
Net Change In Cash	-$36.10M	$47.61M
YoY Change	-175.82%	-306.67%
FREE CASH FLOW
Cash From Operating Activities	-$37.42M	-$33.67M
Capital Expenditures	-$22.00K	-$50.00K
Free Cash Flow	-$37.39M	-$33.62M
YoY Change	11.24%	45.23%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q1	dei	Amendment Flag AmendmentFlag	false
CY2022Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2022Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001559053
CY2022Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2016Q1	prta	Buildtosuit Lease Termof Contract BuildtosuitLeaseTermofContract	P7Y9M30D
CY2022Q1	dei	Document Type DocumentType	10-Q
CY2022Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2022Q1	dei	Document Period End Date DocumentPeriodEndDate	2022-03-31
CY2022Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2022Q1	dei	Entity File Number EntityFileNumber	001-35676
CY2022Q1	dei	Entity Registrant Name EntityRegistrantName	PROTHENA CORPORATION PUBLIC LIMITED COMPANY
CY2022Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	L2
CY2022Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-1111119
CY2022Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	77 Sir John Rogerson’s Quay, Block C
CY2022Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Grand Canal Docklands
CY2022Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Dublin 2,
CY2022Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	D02 VK60,
CY2022Q1	dei	Entity Address Country EntityAddressCountry	IE
CY2022Q1	dei	Country Region CountryRegion	353
CY2022Q1	dei	City Area Code CityAreaCode	1
CY2022Q1	dei	Local Phone Number LocalPhoneNumber	236-2500
CY2022Q1	dei	Security12b Title Security12bTitle	Ordinary Shares, par value $0.01 per share
CY2022Q1	dei	Trading Symbol TradingSymbol	PRTA
CY2022Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2022Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2022Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022Q1	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	46806224	shares
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	542994000	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	579094000	USD
CY2022Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	12626000	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5715000	USD
CY2022Q1	us-gaap	Assets Current AssetsCurrent	555620000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	584809000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2012000	USD
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	10664000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	12123000	USD
CY2022Q1	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	9592000	USD
CY2021Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	7071000	USD
CY2022Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1352000	USD
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1352000	USD
CY2022Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2319000	USD
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1999000	USD
CY2022Q1	us-gaap	Assets Noncurrent AssetsNoncurrent	25792000	USD
CY2021Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	24557000	USD
CY2022Q1	us-gaap	Assets Assets	581412000	USD
CY2021Q4	us-gaap	Assets Assets	609366000	USD
CY2022Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	9316000	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3691000	USD
CY2022Q1	prta	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	6657000	USD
CY2021Q4	prta	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	6351000	USD
CY2022Q1	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	669000	USD
CY2021Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	0	USD
CY2022Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	8844000	USD
CY2021Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	7657000	USD
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	6050000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	5940000	USD
CY2022Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	4960000	USD
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	9813000	USD
CY2022Q1	us-gaap	Liabilities Current LiabilitiesCurrent	36496000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	33452000	USD
CY2022Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	100642000	USD
CY2021Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	102933000	USD
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4834000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	6386000	USD
CY2022Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	553000	USD
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	553000	USD
CY2022Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	106029000	USD
CY2021Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	109872000	USD
CY2022Q1	us-gaap	Liabilities Liabilities	142525000	USD
CY2021Q4	us-gaap	Liabilities Liabilities	143324000	USD
CY2022Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q4	prta	Deferred Shares Par Value DeferredSharesParValue	22
CY2022Q1	prta	Deferred Shares Par Value DeferredSharesParValue	22
CY2022Q1	prta	Deferred Shares Value DeferredSharesValue	0	USD
CY2021Q4	prta	Deferred Shares Value DeferredSharesValue	0	USD
CY2022Q1	prta	Deferred Shares Shares Authorized DeferredSharesSharesAuthorized	10000	shares
CY2021Q4	prta	Deferred Shares Shares Authorized DeferredSharesSharesAuthorized	10000	shares
CY2022Q1	prta	Deferred Shares Share Outstanding DeferredSharesShareOutstanding	0	shares
CY2021Q4	prta	Deferred Shares Share Outstanding DeferredSharesShareOutstanding	0	shares
CY2022Q1	prta	Deferred Shares Share Issued DeferredSharesShareIssued	0	shares
CY2021Q4	prta	Deferred Shares Share Issued DeferredSharesShareIssued	0	shares
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q1	us-gaap	Common Stock Value CommonStockValue	467000	USD
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	466000	USD
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	46749766	shares
CY2022Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	46749766	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	46660294	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	46660294	shares
CY2022Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1190764000	USD
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1181630000	USD
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-752344000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-716054000	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	438887000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	466042000	USD
CY2022Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	581412000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	609366000	USD
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1153000	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	160000	USD
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	27262000	USD
CY2021Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	21144000	USD
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11835000	USD
CY2021Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11125000	USD
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	39097000	USD
CY2021Q1	us-gaap	Operating Expenses OperatingExpenses	32269000	USD
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-37944000	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-32109000	USD
CY2022Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	53000	USD
CY2021Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	11000	USD
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-70000	USD
CY2021Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	23000	USD
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-17000	USD
CY2021Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	34000	USD
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-37961000	USD
CY2021Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-32075000	USD
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1671000	USD
CY2021Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4660000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-36290000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-36735000	USD
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.78
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.78
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.91
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.91
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	46704000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	46704000	shares
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	40250000	shares
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	40250000	shares
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-36290000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-36735000	USD
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	182000	USD
CY2021Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	304000	USD
CY2022Q1	prta	Sharebased Compensationnonrestructuring SharebasedCompensationnonrestructuring	7660000	USD
CY2021Q1	prta	Sharebased Compensationnonrestructuring SharebasedCompensationnonrestructuring	6176000	USD
CY2022Q1	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-2521000	USD
CY2021Q1	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	4622000	USD
CY2022Q1	prta	Amortizationofrightofuseasset Amortizationofrightofuseasset	1459000	USD
CY2021Q1	prta	Amortizationofrightofuseasset Amortizationofrightofuseasset	1400000	USD
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	0	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-14000	USD
CY2022Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	7104000	USD
CY2021Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	5259000	USD
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1745000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-2851000	USD
CY2022Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1442000	USD
CY2021Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1337000	USD
CY2022Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-1104000	USD
CY2021Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	0	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-37415000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-33666000	USD
CY2022Q1	us-gaap	Payments To Acquire Machinery And Equipment PaymentsToAcquireMachineryAndEquipment	22000	USD
CY2021Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2960000	USD
CY2021Q1	us-gaap	Payments To Acquire Machinery And Equipment PaymentsToAcquireMachineryAndEquipment	48000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-22000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-48000	USD
CY2022Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1488000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1337000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	81327000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-36100000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	47613000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	580446000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	298084000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	544346000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	345697000	USD
CY2022Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	9000	USD
CY2021Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	402000	USD
CY2022Q1	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	13000	USD
CY2021Q1	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	0	USD
CY2022Q1	prta	Non Cash Financing Receivable From Option Exercises NonCashFinancingReceivableFromOptionExercises	0	USD
CY2021Q1	prta	Non Cash Financing Receivable From Option Exercises NonCashFinancingReceivableFromOptionExercises	123000	USD
CY2022Q1	prta	Offering Costs Included In Accounts Payable And Accrued Liabilities OfferingCostsIncludedInAccountsPayableAndAccruedLiabilities	0	USD
CY2021Q1	prta	Offering Costs Included In Accounts Payable And Accrued Liabilities OfferingCostsIncludedInAccountsPayableAndAccruedLiabilities	313000	USD
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	542994000	USD
CY2021Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	342993000	USD
CY2022Q1	us-gaap	Restricted Cash Current RestrictedCashCurrent	0	USD
CY2021Q1	us-gaap	Restricted Cash Current RestrictedCashCurrent	1352000	USD
CY2022Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1352000	USD
CY2021Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1352000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	544346000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	345697000	USD
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	466042000	USD
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7660000	USD
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1475000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-36290000	USD
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	438887000	USD
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	184006000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	6176000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3083000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-36735000	USD
CY2021Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	234584000	USD
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-752300000	USD
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	543000000	USD
CY2022Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the Condensed Consolidated Financial Statements in conformity with GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures. On an ongoing basis, management evaluates its estimates, including critical accounting policies or estimates related to revenue recognition, share-based compensation, research and development expenses and leases. The Company bases its estimates on historical experience and on various other market specific and other relevant assumptions that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Because of the uncertainties inherent in such estimates, actual results may differ materially from these estimates.</span></div>
CY2022Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment and Concentration of Risks</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates in one segment. The Company’s chief operating decision maker (the “CODM”), its Chief Executive Officer, manages the Company’s operations on a consolidated basis for purposes of allocating resources. When evaluating the Company’s financial performance, the CODM reviews all financial information on a consolidated basis.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentration of credit risk consist of cash and cash equivalents and accounts receivable. The Company places its cash equivalents with high credit quality financial institutions and, by policy, limits the amount of credit exposure with any one financial institution. Deposits held with banks may exceed the amount of insurance provided on such deposits. The Company has not experienced any losses on its deposits of cash and cash equivalents and its credit risk exposure is up to the extent recorded on the Company's Consolidated Balance Sheet.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The were no receivables recorded in the Condensed Consolidated Balance Sheet as of March 31, 2022. The Company's credit risk exposure is up to the extent recorded on the Company's Condensed Consolidated Balance Sheet.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s business is primarily conducted in U.S. dollars except for its agreements with contract manufacturers for drug supplies which are denominated in Euros and other foreign currencies. The Company recorded a loss on foreign currency exchange rate differences of approximately $70,000 and a gain of $24,000 during the three months ended March 31, 2022 and 2021, respectively. If the Company increases its business activities that require the use of foreign currencies, it may be exposed to losses if the Euro and other such currencies continue to strengthen against the U.S. dollar.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2022, and December 31, 2021, $1.9 million and $2.0 million, respectively, of the Company’s property and equipment, net were held in the U.S. and nominal amounts were in Ireland.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not own or operate facilities for the manufacture, packaging, labeling, storage, testing or distribution of nonclinical or clinical supplies of any of its drug candidates. The Company instead contracts with and relies on third-parties to manufacture, package, label, store, test and distribute all preclinical development and clinical supplies of our drug candidates, and it plans to continue to do so for the foreseeable future. The Company also relies on third-party consultants to assist in managing these third-parties and assist with its manufacturing strategy.</span></div>
CY2022Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Before Reclassification And Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax	70000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Before Reclassification And Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax	-24000	USD
CY2022Q1	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	9764000	USD
CY2021Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	9758000	USD
CY2022Q1	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	1393000	USD
CY2021Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	1393000	USD
CY2022Q1	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	1346000	USD
CY2021Q4	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	1322000	USD
CY2022Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	12503000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	12473000	USD
CY2022Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	10638000	USD
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	10461000	USD
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1865000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2012000	USD
CY2022Q1	us-gaap	Depreciation Depreciation	200000	USD
CY2021Q1	us-gaap	Depreciation Depreciation	300000	USD
CY2022Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4015000	USD
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	8644000	USD
CY2022Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	414000	USD
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	764000	USD
CY2022Q1	us-gaap	Other Sundry Liabilities Current OtherSundryLiabilitiesCurrent	531000	USD
CY2021Q4	us-gaap	Other Sundry Liabilities Current OtherSundryLiabilitiesCurrent	405000	USD
CY2022Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	4960000	USD
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	9813000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-36290000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-36735000	USD
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	46704000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	46704000	shares
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	40250000	shares
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	40250000	shares
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.78
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.78
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.91
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.91
CY2016Q1	prta	Operating Lease Area OperatingLeaseArea	128751	sqft
CY2022Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y9M
CY2016Q1	us-gaap	Lease Expiration Date1 LeaseExpirationDate1	2023-12-31
CY2016Q2	us-gaap	Capital Leases Future Minimum Payments Due CapitalLeasesFutureMinimumPaymentsDue	39200000	USD
CY2022Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	1600000	USD
CY2021Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	1600000	USD
CY2022Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	1600000	USD
CY2021Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	1500000	USD
CY2022Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0425
CY2016Q4	prta	Operating Leases Improvement Allowance OperatingLeasesImprovementAllowance	14200000	USD
CY2018Q3	prta	Operating Leases Sublease Rentals Areaof Sublease Rental OperatingLeasesSubleaseRentalsAreaofSubleaseRental	46641	sqft
CY2022Q1	us-gaap	Sublease Income SubleaseIncome	700000	USD
CY2021Q1	us-gaap	Sublease Income SubleaseIncome	700000	USD
CY2018Q3	prta	Subleaserentals Annual Base Rent Initial Amount SubleaserentalsAnnualBaseRentInitialAmount	2700000	USD
CY2018Q3	prta	Operating Leases Sublease Rentals Percent Annual Rent Increase OperatingLeasesSubleaseRentalsPercentAnnualRentIncrease	0.035
CY2018Q3	prta	Operating Leases Sublease Rentals Termof Contract OperatingLeasesSubleaseRentalsTermofContract	P5Y2M12D
CY2018Q3	prta	Operating Leases Sublease Rentals Percentof Rental Gain Attributableto Sublandlord OperatingLeasesSubleaseRentalsPercentofRentalGainAttributabletoSublandlord	0.50
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	4852000	USD
CY2022Q1	us-gaap	Lessor Operating Lease Payments To Be Received Remainder Of Fiscal Year LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear	2294000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	6535000	USD
CY2022Q1	us-gaap	Lessor Operating Lease Payments To Be Received Next Twelve Months LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths	3019000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	0	USD
CY2022Q1	us-gaap	Lessor Operating Lease Payments To Be Received Two Years LessorOperatingLeasePaymentsToBeReceivedTwoYears	0	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	0	USD
CY2022Q1	us-gaap	Lessor Operating Lease Payments To Be Received Three Years LessorOperatingLeasePaymentsToBeReceivedThreeYears	0	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	11387000	USD
CY2022Q1	us-gaap	Lessor Operating Lease Payments To Be Received LessorOperatingLeasePaymentsToBeReceived	5313000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	433000	USD
CY2022Q1	prta	Lessee Operating Lease Liability Nominal Payments LesseeOperatingLeaseLiabilityNominalPayments	70000	USD
CY2022Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	10884000	USD
CY2022Q1	us-gaap	Purchase Obligation PurchaseObligation	16800000	USD
CY2022Q1	us-gaap	Contractual Obligation ContractualObligation	400000	USD
CY2022Q1	us-gaap	Purchase Obligation PurchaseObligation	16789000	USD
CY2022Q1	us-gaap	Purchase Obligation Future Minimum Payments Remainder Of Fiscal Year PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear	16789000	USD
CY2022Q1	us-gaap	Purchase Obligation Due In Next Twelve Months PurchaseObligationDueInNextTwelveMonths	0	USD
CY2022Q1	us-gaap	Purchase Obligation Due In Second Year PurchaseObligationDueInSecondYear	0	USD
CY2022Q1	us-gaap	Purchase Obligation Due In Third Year PurchaseObligationDueInThirdYear	0	USD
CY2022Q1	us-gaap	Purchase Obligation Due In Fourth Year PurchaseObligationDueInFourthYear	0	USD
CY2022Q1	prta	Purchase Obligation To Be Paid After Year Four PurchaseObligationToBePaidAfterYearFour	0	USD
CY2022Q1	prta	Purchaseand Contractual Obligation Total PurchaseandContractualObligationTotal	17187000	USD
CY2022Q1	prta	Purchaseand Contractual Obligation Remainderof Fiscal Year PurchaseandContractualObligationRemainderofFiscalYear	16850000	USD
CY2022Q1	prta	Purchase And Contractual Obligation Due In Year One PurchaseAndContractualObligationDueInYearOne	59000	USD
CY2022Q1	prta	Purchaseand Contractual Obligation Duein Second Year PurchaseandContractualObligationDueinSecondYear	49000	USD
CY2022Q1	prta	Purchaseand Contractual Obligation Duein Third Year PurchaseandContractualObligationDueinThirdYear	49000	USD
CY2022Q1	prta	Purchaseand Contractual Obligation Duein Fourth Year PurchaseandContractualObligationDueinFourthYear	45000	USD
CY2022Q1	prta	Purchase And Contractual Obligation Due After Fourth Year PurchaseAndContractualObligationDueAfterFourthYear	135000	USD
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	0	USD
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	46749766	shares
CY2022Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	46749766	shares
CY2022Q1	prta	Numberof Votes NumberofVotes	1	vote
CY2022Q1	prta	Deferred Shares Shares Authorized DeferredSharesSharesAuthorized	10000	shares
CY2022Q1	prta	Deferred Shares Par Value DeferredSharesParValue	22
CY2022Q1	prta	Deferred Shares Share Outstanding DeferredSharesShareOutstanding	0	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	1741936	shares
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	2550977	shares
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1372587	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	1407681	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	10318524	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	21.49
CY2021Q1	prta	Number Of Ordinary Shares Tendered For Exchange Under The Option Exchage NumberOfOrdinarySharesTenderedForExchangeUnderTheOptionExchage	2100000	shares
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1400000	shares
CY2021Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	22.85
CY2021Q1	prta	Share Based Compensation Arrangement By Share Based Payment Award Options Minimum Exchange Threshold Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMinimumExchangeThresholdExercisePrice	17.63
CY2022Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	83600000	USD
CY2022Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y10M24D
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	7660000	USD
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	6176000	USD
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.821
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.813
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.019
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.010
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	15.09
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2021Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	23.14
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	8684322	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	19.20
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y11M23D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	269182000	USD
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1741936	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	32.93
CY2022Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	89472	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	16.49
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	18262	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	49.88
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	0	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	0
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	10318524	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	21.49
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y3M7D
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	167897000	USD
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	9781926	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	21.03
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P7Y1M28D
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	162879000	USD
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	5512892	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	16.58
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y9M10D
CY2022Q1	prta	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value Related To Vested Options ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueRelatedToVestedOptions	110847000	USD
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1700000	USD
CY2021Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4700000	USD
CY2022Q1	prta	Deferred Tax Assets Period Increase Decrease DeferredTaxAssetsPeriodIncreaseDecrease	2500000	USD

Files In Submission

Name	View Source	Status
0001559053-22-000023-index-headers.html	Edgar Link	pending
0001559053-22-000023-index.html	Edgar Link	pending
0001559053-22-000023.txt	Edgar Link	pending
0001559053-22-000023-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
prta-20220331.htm	Edgar Link	pending
prta-20220331.xsd	Edgar Link	pending
prta-20220331_cal.xml	Edgar Link	unprocessable
prta-20220331_def.xml	Edgar Link	unprocessable
prta-20220331_htm.xml	Edgar Link	completed
prta-20220331_lab.xml	Edgar Link	unprocessable
prta-20220331_pre.xml	Edgar Link	unprocessable
prta2022q110-qxex311.htm	Edgar Link	pending
prta2022q110-qxex312.htm	Edgar Link	pending
prta2022q110-qxex321.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PRTA
PROTHENA CORP PUBLIC LTD CO Stock $prta

2022 Q1 Form 10-Q Financial Statement

#000155905322000023 Filed on May 05, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PRTA PROTHENA CORP PUBLIC LTD CO Stock $prta

2022 Q1 Form 10-Q Financial Statement

#000155905322000023 Filed on May 05, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PRTA
PROTHENA CORP PUBLIC LTD CO Stock $prta